Doc Code: AP.PRE.REQ	U.S. Patent and	Trademark Office	PTO/SB/33 (07-05) se through xx/xx/200x. OMB 0651-00xx ; U.S. DEPARTMENT OF COMMERCE ess it displays a valid OMB control number.
Ĕ)		Docket Number (Optional)	
PRE-APPEAL BRIEF REQUEST FOR REV	IEVV		
	Application N	Number	Filed
	09/980,954-Conf. #3440		June 5, 2000
	First Named Inventor Akira Kaji et al.		
	Art Unit		Examiner
	1656		D. J. Steadman
The review is requested for the reason(s) stated on the att Note: No more than five (5) pages may be provided		s) .	
I am the applicant /inventor.	-	Jhn	R. Van Cetasturil
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(bis enclosed. (Form PTO/SB/96))) (n R. Van Amsterdam ped or printed name
x attorney or agent of record.			
Registration number 40,212		•	(647) 646 9000
attorney or agent acting under 37 CFR 1.34.			(617) 646-8000 Telephone number
Registration number if acting under 37 CFR 1.34.			ecember 4, 2007
NOTE: Signatures of all the inventors or assignees of record of the Submit multiple forms if more than one signature is required, see	ne entire interes below*.	t or their repres	
*Total of1 forms are submitted.			

Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class-Mail, in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. (Sylvana Householder) Dated: December 4, 2007 Signature: 4

Serial No. 09/980,954 Conf. No. 3440

ARGUMENT FOR PRE-APPEAL BRIEF REQUEST FOR REVIEW

1. Protein Atomic Coordinates Are Not Merely Descriptive Matter

The Examiner's allegation, that the atomic coordinates are merely descriptive matter that is not functional, is incorrect. The atomic coordinates of RRF protein cannot be "merely descriptive" because these coordinates represent an actual three dimensional structure to the skilled person.

See Amendment filed on November 21, 2005 at pages 13-14; Amendment filed on June 6, 2006 at pages 7-8; and Amendment filed on March 21, 2007 at pages 7-8.

2. In Re Gulack Case Is Inapplicable To The Claims

The Examiner's use of <u>In re Gulack</u> in maintaining the claims are obvious in view of the prior art is incorrect.

See Amendment filed on November 21, 2005 at pages 11-13; Amendment filed on June 6, 2006 at pages 7-8; and Amendment filed on March 21, 2007 at pages 8-9.

3. Scope Of Enablement Rejection Does Not Take Into Consideration Claim Language

The Examiner has interpreted the claims as encompassing the use of "homology models". The claims require that the three dimensional structure of the conserved active site contain Arginines at positions 110, 129 and 132, and that the RRF from which the conserved active site structural information is drawn be functional, i.e., that the RRF binds ribosomal RNA and recycles ribosomes.

Docket No. K0448.70012US00

Serial No. 09/980,954

Conf. No. 3440

See Amendment filed on November 21, 2005 at pages 7-10; Amendment filed on June 6, 2006 at page 6; and Amendment filed on March 21, 2007 at pages 5 and 7.

3

4. Broadest Reasonable Interpretation Of The Claims Does Not Include Homology Models

The Examiner's statement that the claims include "homology models" under a broad, but reasonable, interpretation of the claims is incorrect. The Examiner's citation to the specification in support of the claim interpretation is inappropriate in view of the claim language.

See Amendment filed on March 21, 2007 at pages 5-6.